Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Steven Russell

Endocrinology, Diabetes & Metabolism Boston, MA Medical Doctor

NPI 1679554042 CMS profile 439402

55 Fruit St, Wel 501, Boston, MA 02114

Open in the dashboard

General payments

$444,706

55 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$618,928 paid to institutions, not to them · program years 2019–2023

Through program year 2025, Steven Russell of Boston, MA is reported in the CMS Open Payments database as having received $444,706 across 55 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $618,928 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Endocrinology, Diabetes & Metabolism profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,154 2
2024 General $14,743 4
2023 General $348 3
2022 General $1,455 4
2021 General $17,491 4
2020 General $370,070 17
2019 General $39,444 21

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Steven Russell
  • Endocrinology, Diabetes & Metabolism median
  • Middle half of Endocrinology, Diabetes & Metabolism
  • National median

In program year 2025, general payments to Steven Russell were reported at $1,154. Among 5,868 Endocrinology, Diabetes & Metabolism profiles paid that year, the median was $507 and the middle half received between $135 and $1,838.

Show as a table
Year Steven Russell Endocrinology, Diabetes & Metabolism median Middle half National median
2019 $39,444 $494 $123–$2,253 $163
2020 $370,070 $335 $85–$1,841 $114
2021 $17,491 $398 $88–$1,981 $132
2022 $1,455 $364 $88–$1,568 $149
2023 $348 $420 $113–$1,614 $160
2024 $14,743 $440 $121–$1,646 $164
2025 $1,154 $507 $135–$1,838 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic MiniMed, Inc. $348,152 2 payments
  2. Novo Nordisk AS $34,881 24 payments
  3. Medtronic, Inc. $30,631 4 payments
  4. Novo Nordisk Inc $22,945 9 payments
  5. ConvaTec Inc. $5,120 4 payments
  6. Lilly USA, LLC $1,838 1 payment
  7. Dexcom, Inc. $308 4 payments
  8. Beta Bionics, Inc. $283 2 payments
  9. Senseonics, Incorporated $240 1 payment
  10. Mannkind Corporation $119 2 payments
  11. Other $190 2 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Royalty or License $348,152 2 payments
  2. Consulting Fee $33,563 12 payments
  3. Acquisitions $30,574 3 payments
  4. Travel and Lodging $29,765 19 payments
  5. Food and Beverage $1,386 13 payments
  6. Education $850 2 payments
  7. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $240 1 payment
  8. Gift $119 2 payments
  9. Grant $57 1 payment
Products named General payments · program years 2019–2025
  1. InPen Continuous Glucose Monitoring $348,152 2 payments
  2. INPEN SMART INSULIN DELIVERY SYSTEM $15,564 2 payments
  3. InPen Continuous Glucose Monitoring $15,011 1 payment
  4. FIASP $7,368 4 payments
  5. Ryzodeg 70/30 $6,770 6 payments
  6. AQUACEL Ag Advantage Surgical $2,240 2 payments
  7. AQUACEL AG $1,600 1 payment
  8. AQUACEL AG+ $1,280 1 payment
  9. Dexcom G6 Transmitter $308 4 payments
  10. iLet Bionic Pancreas $283 2 payments
  11. Other $1,172 10 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 15 billing codes

Paid by Medicare

$13,624

Medicare's payments for the services billed

Medicare patients

39

Average age 68

Services billed

76

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 64%
Ischemic heart disease 62%
Arthritis 51%
Heart failure 46%
Depression 41%
Atrial fibrillation 33%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

55 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Endocrinology, Diabetes & Metabolism in Massachusetts

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record